Leaflet SYNAGIS 100mg / ml solution for injection

Product code:
W67585001
Quantity:
1
Indicated for:
prevention of respiratory syncytial virus disease
Route of administration:
injectable
Substance:
palivizumab (monoclonal antibody)
ATC
J06BB16 — Antiinfectives for systemic use | Immunoglobulins | Specific immunoglobulins

Precautions:

Anaphylaxis

Anaphylaxis

Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.

Additional monitoring

Additional monitoring

This medicine is subject to additional monitoring.

Breastfeeding warning

Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning

Pregnancy warning

Use during pregnancy only on medical advice.

Palivizumab is a monoclonal antibody used for the prevention of severe respiratory syncytial virus (RSV) infections in infants and children at high risk. It works by binding to the F protein of the virus, preventing its replication.

The medication is administered via intramuscular injection, usually once a month during the RSV season, as directed by your doctor. It is important to follow the administration schedule to ensure optimal protection.

Side effects may include injection site reactions, fever, rash, or, in rare cases, severe allergic reactions.

Patients should inform their doctor about any known allergies or other conditions to ensure the safe use of palivizumab.

Official documents

Added to database:
04/12/2009
Source record updated:
11/10/2023

General data about SYNAGIS 100mg / ml

Substance:
palivizumab
Date of latest medicines list:
01-06-2021
Product code:
W67585001
Concentration:
100mg / ml
Pharmaceutical form:
solution for injection
Quantity:
1
Product type:
Original
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
ABBVIE S.R.L. - ITALIA
Holder:
ASTRAZENECA AB - SUEDIA
Number:
117/1999/04
Shelf life:
3 years

Pharmaceutical forms available for palivizumab

Concentrations available for palivizumab

  • 100mg
  • 100mg/ml
  • 50mg